Chen ZX, Hohmann L, Banjara B, Zhao Y, Diggs K, Westrick SC. Recommendations to protect patients and health care practices from Medicare and Medicaid fraud. J Am Pharm Assoc. 2020 Nov;60(6):e60-5. doi: 10.1016/j.japh.2020.05.011
John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Pead E, Megaw R, Cameron J, Fleming A, Dhillon B, Trucco E, MacGillivray T. Automated detection of age-related macular degeneration in color fundus photography: a systematic review. Surv Ophthalmol. 2019 Jul 1;64(4):498-511. doi: 10.1016/j.survophthal.2019.02.003
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Wilburn J, Twiss J, Kemp K, McKenna SP. A qualitative study of the impact of Crohn's disease from a patient's perspective. Frontline Gastroenterol. 2017;8:68-73. doi: 10.1136/flgastro-2015-100678
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Doward LC, Wilburn J, McKenna SP, Leicester R, Epstein O, Hedley V, Korala S, Twiss J, Jones D, Geraint M. Development and validation of the Bowel Cleansing Impact Review (BOCLIR). Frontline Gastroenterol. 2013 Feb;4(2):112-9. doi: 10.1136/flgastro-2012-100278
Schwab PE. Tobacco survey results/ cigarette sales in pharmacy: consumer research and analysis to support merchandising decisions. Poster presented at the 2010 American College of Apothecaries Mid-Year Meeting; March 2010. Memphis, TN. [abstract] J Am Pharm Assoc. 2010 Mar; 50(2).
Mehta S, Nagar SP, Aparasu R. Unmet prescription medication need in U.S. children. J Am Pharm Assoc. 2009 Nov;49(6):769-76.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Andrews EB, Gilsenan A, Cook SF. Therapeutic Risk Management Interventions: feasibility and Effectiveness. J Am Pharm Assoc. 2004 Jan 1;44(4):491-500.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.
Carlson AM, Stockwell-Morris L, Perfetto EM, Appel AM, Gilsenan AW. Quality of sleep in patients with osteoarthritis treated with extended-release and conventional etodolac. J Am Pharm Assoc. 1998 Jan;38(1):31-6. doi: 10.1016/S1086-5802(16)30297-2